Zolgensma First To Be Subject To New German Data Collection Rules

Price & Reimbursement Body Sets Out New Process

The G-BA has explained in more detail the procedures for mandating post-launch evidence generation under new legislation introduced in 2019.

Germany_Pills
Zolgensma Is The First Drug To Be Affected By Germany's New Data Generation Rules

More from Cell & Gene Therapies

More from Advanced Technologies